Arcturus Therapeutics develops mRNA medicines for rare diseases and a COVID-19 vaccine, KOSTAIVE, with partner CSL Seqirus. ARCT reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Prices, price targets and earnings estimates for ARCT are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in ARCT in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARCT is in one of them and how their past ARCT trades turned out.
Arcturus Therapeutics is a messenger RNA medicines company based in San Diego, California. It develops treatments for rare genetic diseases, including candidates for ornithine transcarbamylase deficiency and cystic fibrosis. The company also develops vaccines, and its KOSTAIVE COVID-19 vaccine is partnered with CSL Seqirus and sold in Japan through Meiji Seika Pharma. Its proprietary LUNAR delivery system and STARR platform are used to build these medicines and vaccines.
